avaohev.blogspot.com
Oxigene (NASDAQ: OXGN), a cancerd and eye disease drug developer basedin Waltham, Mass., has its West Coas office in South San Its shares closed Monday at In a Securities and Exchange Commission filing the company said the compensation deal is “ij recognition of the level of services to be provides by Mr. Shiebler in his capacity as chairman durinh an undefined interim periodf following his assumption of the duties of Shieblerreceived $46,500 last year as a Shiebler’s stock options vest in equal amounts over four starting one year from the date of the grant.
John who was named Oxigened CEOin October, was supposed to be according to an SEC filing, assuminyg his reelection to the boarrd of directors at the annual shareholdert meeting May 28. Oxigene did not give a reasoj why Shiebler instead of Kollins was elected Formerchairman Joel-Tomas Citron, who did not stand for reelection to the received 2008 director compensation of $215,994, includin a monthly base salary as part of his employmentf contract. Shiebler, 67, has been a directof of Oxigenesince 2002. He was the advisorhy vice chairman and CEO of the Americawof , the asset arm of for five years endingv in March 2007 and had been presidengt and CEO of .
Shiebler is a principal in two familgyinvestment businesses. Oxigene’s former president and CEO, Dr. Richard stepped down in October and now headsthe , a nonprofig drug developer in San
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment